DBV Technologies shares back above their MM20 and rebound 2.5%
The Châtillon-based biotech recovers mid-session, in an SBF 120 slightly trending higher. This rebound follows quarterly results accompanied by a warning on going concern, while its patch file against peanut allergy is being reviewed by the US health authority.
A rebound that brings the stock back above its 20-day moving average
The stock of DBV Technologies gains 2.28% to €1.84 and ranks ninth among gainers in the SBF 120, which rises 0.37%. It climbs 8% over one week, bringing it back above its 20-day moving average (MM20) at €1.73 (a gap of +6.13%), while it remains below its 50-day moving average (MM50) at €1.94 and well below its 200-day moving average (MM200) at €2.86.
The RSI at 52 is neutral: the rebound of the week has not pushed the indicator into overbought territory.
Over three months, the stock is still down more than 21%, so the recent rise recovers only a limited part of the decline, all the more so as the €1.57 support remains within reach.
Net short positions follow the same trend: four funds together hold 2.80% of the capital according to the disclosures reviewed, compared with 3.65% thirty days earlier, a decline of 0.85 point that indicates a less pronounced bearish bet than last month.
Going concern in question ahead of the FDA decision
When it published its accounts for the first nine months of 2026 on October 28, the company reported a substantial doubt about its ability to continue as a going concern and indicated that it needed additional capital beyond the third quarter of 2027. It also reminded that it had filed the Viaskin Peanut patch file for children aged 4 to 7, with a request for priority review and a decision expected in the fourth quarter of 2026.
A $50 million ADS offering has just been completed, and a $150 million program has been renewed.
For reference, the company is listed in Paris and on Nasdaq in the form of ADSs (1 ADS for 5 shares), the Paris line being the most liquid and the only one eligible for the PEA (French equity savings plan). The FDA decision, expected this quarter, will be the next known event on the patch file.
